OTLK
Outlook Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Consensus Rating "Strong Buy"
High Gross Profit Margin
Significant Net Income Decline
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About OTLK
Outlook Therapeutics, Inc.
A clinical-stage biopharmaceutical company focused on developing monoclonal antibodies for various ophthalmic indications
Pharmaceutical
01/05/2010
06/14/2016
NASDAQ Stock Exchange
23
09-30
Common stock
111 S. Wood Avenue, Unit #100, Iselin, New Jersey 08830
--
Outlook Therapeutics, Inc., was incorporated in New Jersey on January 5, 2010. The company is a biopharmaceutical company that is the first to obtain marketing authorization for ONS-5010/LYTENAVA (bevacizumab-gamma) ophthalmic preparations in the EU or EU, UK or UK for the treatment of wet age-related macular degeneration, or wet AMD. The company is developing ONS-5010/LYTENAVA as an intravitreal injection for the treatment of wet AMD and retinal diseases.
Company Financials
EPS
OTLK has released its 2025 Q3 earnings. EPS was reported at -0.55, versus the expected -0.39, missing expectations. The chart below visualizes how OTLK has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
OTLK has released its 2025 Q3 earnings report, with revenue of 1.51M, reflecting a YoY change of NaN%, and net profit of -20.15M, showing a YoY change of -145.38%. The Sankey diagram below clearly presents OTLK's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
